The usage and adverse reaction characteristics of Yimucao Injection were summarized from previous literature and research. Methods:CNKI, Wan Fang Data, VIP, SinoMed, PubMed and EMbase databases were searched. The deadline for publication was January 31st, 2020. All study design types were included, and multicenter clinical studies, case reports and randomized controlled clinical studies were analyzed by bibliometrics. Results:A total of 225 literature on the safety of Yimucao Injection were reviewed. Bibliometric analysis of 22 911 patients using Yimucao Injection and ADR showed: the age were mainly from 21 to 44, the time of pregnancy was mainly from 37 to 44 weeks, and there were 3 481 cases of primipara and 2 044 cases of transpara; the main diseases of the patients were postpartum hemorrhage in caesarean section, postpartum hemorrhage and natural postpartum hemorrhage, and the main combined diseases were large gestational children, abnormal amniotic fluid, and gestational diabetes etc; the use of Yimucao Injection involved in different producers, the majority did not specifically mention the number and the manufacturer, and the single dose (ml) was mainly 2 mL, and the main route of administration was intramuscular injection, intrauterine injection and intramuscular injection, and intrauterine injection. The course of treatment was 2 to 3 days; combined drug use was mainly oxytocin, carbendazim aminobutanol, and misoprostol injection; the manifestation of ADR by using Yimucao Injection from different manufacturers were: facial flushing, nausea and vomiting etc. Conclusion:Clinical use of Yimucao Injection is relatively safe, and its adverse reactions are mostly mild.